Bristol-MyersSquibb Co., Biopharmaceutics R&D, One Squibb Dr., Bldg. 105/Room 2474, New Brunswick, New Jersey 08903, USA.
J Pharm Sci. 2010 Jul;99(7):2941-7. doi: 10.1002/jps.22074.
Drug-polymer solid dispersion has been demonstrated as a feasible approach to formulate poorly water-soluble drugs in the amorphous form, for the enhancement of dissolution rate and bioperformance. The solubility (for crystalline drug) and miscibility (for amorphous drug) in the polymer are directly related to the stabilization of amorphous drug against crystallization. Therefore, it is important for pharmaceutical scientists to rationally assess solubility and miscibility in order to select the optimal formulation (e.g., polymer type, drug loading, etc.) and recommend storage conditions, with respect to maximizing the physical stability. This commentary attempts to discuss the concepts and implications of the drug-polymer solubility and miscibility on the stabilization of solid dispersions, review recent literatures, and propose some practical strategies for the evaluation and development of such systems utilizing a working diagram.
药物-聚合物固体分散体已被证明是一种可行的方法,可将水溶性差的药物制成无定形形式,以提高药物的溶解速率和生物利用度。聚合物中的溶解度(对于结晶药物)和混溶性(对于无定形药物)直接关系到无定形药物对结晶的稳定性。因此,对于制药科学家来说,合理评估溶解度和混溶性对于选择最佳配方(例如聚合物类型、药物负载等)以及推荐储存条件以最大限度地提高物理稳定性非常重要。本文试图讨论药物-聚合物溶解度和混溶性对固体分散体稳定性的概念和影响,综述近期文献,并提出利用工作图评估和开发此类系统的一些实用策略。